Treating pathological pain: is KCC2 the key to the gate?

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

The authors acknowledge financial support from Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Fonds de recherche Québec – Santé, Krembil Foundation and Regione Piemonte/University of Turin. Laval University has a patent pending on a family of KCC2 activators not discussed in the current editorial. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.